Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: October 05, 2017
GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
Journal: European journal of endocrinology
Published: August 14, 2014
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Journal: Endocrine-related cancer
Published: July 12, 2014
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Journal: Pancreas
Published: March 18, 2014
Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
Journal: American journal of surgery
Published: November 25, 2013
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Journal: Neuroendocrinology
Published: June 24, 2013
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
Journal: Endocrine-related cancer
Published: April 11, 2013
Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.
Journal: Gastrointestinal cancer research : GCR
Published: March 21, 2013
Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 19, 2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Journal: Endocrine-related cancer
Published: July 19, 2012
Last Updated: 09/26/2026